Navigation Links
North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
Date:7/16/2013

NEW YORK, July 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) – Forecasts To 2017

http://www.reportlinker.com/p01551261/North-American-Drug-Delivery-Technologies-Market-Metered-Dose-Inhalers-Needle-Free-Injectors-Auto-Injectors-Nasal-Sprays-Transdermal-Patches-Nebulizers-Infusion-Pumps-Drug-Eluting-Stents-Sustained-Release-Ocular-Implants-–-Forecasts-To-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

Patent expiry of major blockbuster drugs is a prime concern for pharmaceutical companies, as developing a new chemical entity (NCE) is more expensive and time consuming than a novel drug delivery technology. Therefore, in recent years, several pharmaceutical companies have employed drug delivery technology as a life cycle management tool for some of their blockbuster drugs, the patents for which are set to expire in the near future.

The North American drug delivery market was estimated to be worth $66.7 billion in 2012, and is expected to register a CAGR of 8.9% between 2012 and 2017. Based on the route of administration, the drug delivery market has been classified as oral, pulmonary, injectable, transdermal, implantable, ocular, nasal, transmucosal, and topical. In 2012, oral drug delivery segment dominated the market with a share of approximately 38%, followed by pulmonary drug delivery segment with a 20% share.

The drug delivery technologies that have recently gained importance in the North American market include orodispersible tablet (ODT), dry powder inhalers, transdermal patches, needle-free injectors, auto and pen injectors, and buccal transmucosal tablets; controlled release is the most widely accepted technology. The use of implantable devices for drug delivery is also on a rise.Big pharmaceutical companies such as Pfizer and Merck have established in-house capabilities for the development of drug delivery technologies. On the contrary, many other companies are still relying on specialty companies engaged in the development of drug delivery technologies. High level of competition and increasing need for outsourcing has resulted in the drug delivery market to be fragmented, with several small companies developing novel drug delivery technologies for niche therapeutic applications.The North American drug delivery market is largely dominated by the U.S. (accounting for about 89% of the overall market). The key drivers for the U.S. drug delivery market are the well established pharmaceutical industry , healthcare reforms, and favourable changes in the FDA review process. Factors such as low cost drug manufacturing and rising number of drug delivery formulations and devices are propelling the Canadian market.Key players in the drug delivery technologies market are 3M Company (U.S.), Aptalis Pharma, Inc. (U.S.), Baxter International, Inc. (U.S.), Becton, Dickinson & Co. (U.S.), Catalent Pharma Solutions (U.S.), The Dow Chemical Company (U.S.), Endo Pharmaceuticals (U.S.), Johnson & Johnson (U.S.), Nektar Therapeutics (U.S.) and Valeant Pharmaceuticals (Canada).

Scope of the report:

This research report categorizes and analyzes the North American Drug Delivery Technologies market on the basis of routes of administration. These markets are further divided into segments and sub-segments, to provide exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (U.S and Canada), to provide in-depth information on the North American market scenario.

North American drug delivery technologies market, by segment:

Oral Drug DeliveryControlled ReleaseOrodispersible Tablets (ODT) and Taste MaskingOthers Pulmonary Drug DeliveryDry Powder InhalersMetered Dose InhalersNebulizers Transdermal Drug DeliveryPassive Drug DeliveryReservoir SystemMatrix System Active Drug Delivery IontophoresisMicroporationOthers Injectable Drug DeliveryConventional Injection DevicesFillable SyringesPrefilled Syringes Self-injection DevicesNeedle-free InjectorsAuto-injectors or Safety Syringe DevicesPen Injectors Others Ocular Drug DeliveryEye DropsOintment and GelOthers Nasal Drug DeliveryNasal DropsNasal SpraysNasal InhalersOthers Topical Drug DeliveryLiquid FormulationsSemisolid FormulationsSolid Formulations Implantable Drug DeliveryDrug-Eluting StentsImplantable Infusion PumpsContraceptive ImplantsIntravitreal ImplantsBrachytherapy Seeds Transmucosal Drug DeliveryOral (Buccal and Sublingual)Others (Rectal and Vaginal)

North America drug delivery technologies market, by country:

U.SCanada 1 INTRODUCTION 221.1 KEY TAKE-AWAYS 221.2 REPORT DESCRIPTION 221.3 MARKETS COVERED 241.4 STAKEHOLDERS 261.5 RESEARCH METHODOLOGY 261.5.1 MARKET SIZE 261.5.2 MARKET SHARE 271.5.3 KEY DATA POINTS FROM SECONDARY SOURCES 271.5.4 KEY DATA POINTS FROM PRIMARY SOURCES 281.5.5 ASSUMPTIONS 282 EXECUTIVE SUMMARY 293 MARKET OVERVIEW 333.1 INTRODUCTION 343.2 MARKET SEGMENTATION 343.3 MARKET DYNAMICS 363.3.1 DRIVERS 363.3.1.1 Patent Cliff and Increased Competition to Increase Adoption Rate 363.3.1.2 Improving Patient Compliance and Acceptability, An Impetus to the Drug Delivery Systems Market 373.3.1.3 Increasing Focus on Pediatric and Geriatric Patients to Boost the Growth 383.3.1.4 Increasing Incidence of Chronic Diseases in North America to Enhance Demand 383.3.2 RESTRAINTS 393.3.2.1 Drug Failures and Recalls Mar Market Growth 393.3.2.2 Technical Barriers Restrict Growth 40

3.3.3 OPPORTUNITIES 41

3.3.3.1 Collaborations Between Pharmaceutical Companies and Drug Delivery Firms 41

3.3.3.2 Self-administration and Home Care Drug Delivery Devices 42

3.3.3.3 Expanding therapeutic applications of drug delivery technologies 43

3.3.4 TARGETED DRUG DELIVERY 43

3.3.4.1 Passive Systems Contribute 60% to the Targeted Drug Delivery Market 44

3.3.4.2 Active Targeted Drug Delivery has Major Applications in Cancer Therapy 44

3.3.4.3 Companies Focus on Novel Targeted Drug Delivery 44

3.3.5 BURNING ISSUES 45

3.3.5.1 Striking Right Partnerships 45

3.3.5.2 Improving the Bioavailability of Drugs 46

3.4 REGULATORY ENVIRONMENT 47

3.4.1 STRINGENT REGULATIONS FOR PHARMACEUTICAL DRUGS IN NORTH AMERICA 47

3.4.1.1 The Approval Process is Complex, Time-consuming, and Expensive 47

3.4.2 EFFECT OF THE U.S. HEALTHCARE REFORMS ON THE DRUG DELIVERY INDUSTRY 48

3.4.2.1 Drug Delivery Companies to Benefit from the Affordable Care Act (ACA) Reform in the Long Run 48

3.4.3 REGULATIONS RELATED TO THE APPROVAL OF CONTROLLED RELEASE DRUGS 48

3.5 PORTER'S FIVE FORCES ANALYSIS 49

3.5.1 THREAT OF NEW ENTRANTS 50

3.5.2 THREAT OF SUBSTITUTES 50

3.5.3 COMPETITOR'S RIVALRY 50

3.5.4 BARGAINING POWER OF SUPPLIERS 51

3.5.5 BARGAINING POWER OF BUYERS 51

3.6 VALUE CHAIN ANALYSIS 52

3.7 MARKET SHARE ANALYSIS 53

3.7.1 PULMONARY DRUG DELIVERY 53

3.7.1.1 U.S. 53

3.7.1.2 Canada 55

3.7.2 TRANSDERMAL DRUG DELIVERY 55

3.7.2.1 U.S. 55

3.7.2.2 Canada 57

3.7.3 INECTABLE DRUG DELIVERY DEVICES 58

3.7.3.1 U.S. 58

3.7.3.2 Canada 60

3.7.4 IMPLANTABLE DRUG DELIVERY 61

3.7.4.1 U.S. 61

3.7.4.2 Canada 62

3.7.5 OTHER DRUG DELIVERY SEGMENTS 63

4 NORTH AMERICA DRUG DELIVERY MARKET, BY TECHNOLOGY 65

4.1 INTRODUCTION 66

4.1.1 DRUG DELIVERY MARKET WITNESSING TECHNOLOGICAL ADVANCEMENTS 66

4.2 OPPORTUNITY MATRIX 68

4.3 ORAL DRUG DELIVERY 70

4.3.1 REFORMULATION STRATEGIES & ESTABLISHING IN-HOUSE CAPABILITIES HELP IN SIGNIFICANT GROWTH 70

4.3.2 CONTROLLED RELEASE 72

4.3.3 ORODISPERSIBLE TABLETS (ODT) AND TASTE MASKING 75

4.3.4 OTHERS 76

4.4 PULMONARY DRUG DELIVERY 78

4.4.1 THERAPEUTIC APPLICATIONS OF PULMONARY DELIVERY 79

4.4.1.1 Application of pulmonary delivery for non-respiratory therapies is a growing opportunity 79

4.4.2 METERED DOSE INHALERS (MDI) 82

4.4.3 DRY POWDER INHALERS (DPI) 83

4.4.4 NEBULIZERS 84

4.5 TRANSDERMAL DRUG DELIVERY 86

4.5.1 PASSIVE TRANSDERMAL DRUG DELIVERY 88

4.5.1.1 Matrix system 90

4.5.1.2 Reservoir system 90

4.5.2 ACTIVE TRANSDERMAL DRUG DELIVERY 91

4.5.2.1 Microporation 92

4.5.2.2 Iontophoresis 93

4.5.2.3 Others 93

4.6 INJECTABLE DRUG DELIVERY 94

4.6.1 INJECTABLE DRUG DELIVERY MARKET WITNESSING DEVELOPMENTS RELATED TO PRODUCT IMPROVEMENT 94

4.6.2 CONVENTIONAL INJECTABLE DRUG DELIVERY DEVICES 97

4.6.2.1 Low manufacturing cost and affordable prices: key driver for conventional injection devices 97

4.6.2.2 Fillable 99

4.6.2.3 Prefilled 100

4.6.3 SELF-INJECTION DEVICES 100

4.6.3.1 Self-injection devices reduce overall treatment cost 101

4.6.3.2 Pen injectors 103

4.6.3.3 Needle-free injectors 104

4.6.3.4 Auto injectors 105

4.6.4 OTHERS 106

4.7 OCULAR DRUG DELIVERY 108

4.7.1 EYE DROPS 110

4.7.2 OINTMENTS AND GELS 111

4.7.3 OTHERS 112

4.8 NASAL DRUG DELIVERY 114

4.8.1 NASAL DRUG DELIVERY PREFERRED FOR LOCALLY ACTING DRUGS AND DELIVERY OF VACCINES 114

4.8.2 NASAL SPRAYS 116

4.8.3 NASAL INHALERS 118

4.8.4 NASAL DROPS 119

4.8.5 OTHERS 120

4.9 TOPICAL DRUG DELIVERY 121

4.9.1 TOPICAL DELIVERY MAJORLY ADOPTED FOR DERMATOLOGY DRUGS 121

4.9.2 SEMI-SOLID FORMULATIONS 124

4.9.3 LIQUID FORMULATIONS 125

4.9.4 SOLID FORMULATIONS 126

4.10 IMPLANTABLE DRUG DELIVERY 128

4.10.1 DRUG- ELUTING STENTS 130

4.10.2 IMPLANTABLE INFUSION PUMPS 132

4.10.2.1 Implantable infusion pumps largely used for therapies of chronic ailments 133

4.10.3 CONTRACEPTIVE IMPLANTS 134

4.10.4 INTRAVITREAL IMPLANTS 134

4.10.5 BRACHYTHERAPY SEEDS 136

4.11 TRANSMUCOSAL DRUG DELIVERY 138

4.11.1 ORAL (BUCCAL AND SUBLINGUAL) 140

4.11.2 OTHERS (RECTAL, VAGINAL) 142

5 GEOGRAPHIC ANALYSIS 144

5.1 INTRODUCTION 145

5.2 UNITED STATES 147

5.2.1 WELL-ESTABLISHED U.S. PHARMACEUTICAL INDUSTRY DRIVES THE DRUG DELIVERY MARKET 147

5.2.2 FAVORABLE CHANGES IN THE FDA TO ACCELERATE DRUG REVIEW AND APPROVAL PROCESSES 148

5.2.3 U.S. HEALTHCARE REFORMS WILL IMPACT THE DRUG DELIVERY MARKET 148

5.3 CANADA 159

5.3.1 INSURANCE COVERAGE FAVORING THE GROWTH OF CANADIAN DRUG DELIVERY TECHNOLOGY MARKET 159

5.3.2 RISE IN NUMBER OF APPROVALS AND AGREEMENTS IN THE CANADA DRUG DELIVERY MARKET 159

6 COMPETITIVE LANDSCAPE 171

6.1 INTRODUCTION 171

6.1.1 MERGERS & ACQUISITIONS AND AGREEMENTS & COLLABORATIONS WERE THE KEY STRATEGIES ADOPTED BY PLAYERS 172

6.2 MERGERS & ACQUISITIONS 172

6.3 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS 175

6.4 NEW PRODUCT LAUNCH 177

6.5 OTHER DEVELOPMENTS 179

7 COMPANY PROFILES 187

(Overview, Financials, Products & Services, Strategy, & Developments)*

7.1 3M COMPANY 187

7.2 APTALIS PHARMA, INC. 194

7.3 BAXTER INTERNATIONAL, INC. 199

7.4 BECTON, DICKINSON AND COMPANY 205

7.5 CATALENT PHARMA SOLUTIONS 212

7.6 CIMA LABS 219

7.7 ENDO HEALTH SOLUTIONS, INC. 225

7.8 JOHNSON & JOHNSON, INC. 231

7.9 NEKTAR THERAPEUTICS, INC. 238

7.10 OPTINOSE AS 242

7.11 PSIVIDA CORPORATION 246

7.12 THE DOW CHEMICAL COMPANY 251

7.13 VALEANT PHARMACEUTICALS 257

*Details on Financials, Product & Services, Strategy, & Developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 NORTH AMERICA DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 31TABLE 2 KEY DRUG DELIVERY TECHNOLOGY PROVIDERS & MARKETER COMPANIES 63TABLE 3 NORTH AMERICAN DRUG DELIVERY MARKET,BY ROUTE OF ADMINISTRATION, 2010 – 2017 67TABLE 4 NORTH AMERICAN ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 71TABLE 5 NORTH AMERICAN ORAL DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 72TABLE 6 CONTROLLED RELEASE DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 74TABLE 7 ODT & TASTE-MASKING MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 76TABLE 8 OTHER ORAL DRUG DELIVERY TECHNOLOGIES MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 77TABLE 9 NORTH AMERICAN PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION) 80TABLE 10 NORTH AMERICAN PULMONARY DRUG DELIVERY MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 81TABLE 11 COMPARATIVE OVERVIEW OF PULMONARY DRUG DELIVERY DEVICES 81TABLE 12 METERED DOSE INHALATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 83TABLE 13 DRY POWDER INHALATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 84TABLE 14 NEBULIZERS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 85TABLE 15 NORTH AMERICAN TRANSDERMAL DRUG DELIVERY MARKET,BY MODE OF DELIVERY, 2010 – 2017 ($MILLION) 87TABLE 16 NORTH AMERICAN TRANSDERMAL DRUG DELIVERY MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 88TABLE 17 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 89TABLE 18 PASSIVE TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 90TABLE 19 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 91TABLE 20 ACTIVE TRANSDERMAL DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 92TABLE 21 NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2010 – 2017 ($BILLION) 95TABLE 22 NORTH AMERICAN INJECTABLE DRUG DELIVERY MARKET, BY COUNTRY, 2010 – 2017 ($BILLION) 96TABLE 23 CONVENTIONAL INJECTION DEVICES MARKET, BY PRODUCT,2010 – 2017 ($BILLION) 98TABLE 24 CONVENTIONAL INJECTION DEVICES MARKET, BY COUNTRY,2010 – 2017 ($BILLION) 99TABLE 25 SELF-INJECTION DEVICES MARKET, BY PRODUCT,2010 – 2017 ($MILLION) 102TABLE 26 SELF-INJECTION DEVICES MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 103TABLE 27 OTHER INJECTORS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 107TABLE 28 NORTH AMERICAN OCULAR DRUG DELIVERY MARKET,BY FORMULATION, 2010 – 2017 ($MILLION) 109TABLE 29 NORTH AMERICAN OCULAR DRUG DELIVERY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 110TABLE 30 EYE DROP DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 111TABLE 31 OINTMENT & GEL DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 112TABLE 32 OTHER OCULAR DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 113TABLE 33 NORTH AMERICAN NASAL DRUG DELIVERY MARKET, BY FORMULATION, 2010 – 2017 ($MILLION) 115TABLE 34 NORTH AMERICAN NASAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 116TABLE 35 NASAL SPRAY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 117TABLE 36 NASAL INHALER MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 118TABLE 37 NASAL DROPS MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 119TABLE 38 OTHER NASAL DELIVERY FORMULATIONS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 120TABLE 39 NORTH AMERICAN TOPICAL DRUG DELIVERY MARKET,BY FORMULATION, 2010 – 2017 ($MILLION) 123TABLE 40 NORTH AMERICAN TOPICAL DRUG DELIVERY MARKET, BY COUNTRY, 2010 – 2017 ($MILLION) 124TABLE 41 SEMI-SOLID TOPICAL FORMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 125TABLE 42 LIQUID TOPICAL FORMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 126TABLE 43 SOLID TOPICAL FORMULATION MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 127TABLE 44 NORTH AMERICAN IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE, 2010 – 2017 ($MILLION) 129TABLE 45 IMPLANTABLE DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 130TABLE 46 DRUG-ELUTING STENTS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 132TABLE 47 IMPLANTABLE INFUSION PUMPS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 133TABLE 48 CONTRACEPTIVE IMPLANTS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 134TABLE 49 INTRAVITREAL IMPLANTS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 135TABLE 50 BRACHYTHERAPY SEEDS MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 137TABLE 51 NORTH AMERICAN TRANSMUCOSAL DRUG DELIVERY MARKET,BY MUCOSA TYPE, 2010 – 2017 ($MILLION) 139TABLE 52 NORTH AMERICAN TRANSMUCOSAL DRUG DELIVERY MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 140TABLE 53 ORAL TRANSMUCOSAL DRUG DELIVERY MARKET, BY COUNTRY,2010 – 2017 ($MILLION) 141TABLE 54 OTHER TRANSMUCOSAL DRUG DELIVERY TECHNOLOGIES MARKET,BY COUNTRY, 2010 – 2017 ($MILLION) 142TABLE 55 NORTH AMERICAN DRUG DELIVERY MARKET, BY COUNTRY,2010 - 2017 ($MILLION) 146TABLE 56 U.S.: DRUG DELIVERY TECHNOLOGIES MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 149TABLE 57 U.S.: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,2010 – 2017 ($MILLION) 150TABLE 58 NORTH AMERICAN PULMONARY DRUG DELIVERY MARKET,BY DEVICE TYPE, 2010 – 2017 ($MILLION) 151TABLE 59 U.S.: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($MILLION) 152TABLE 60 U.S.: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY,2010 – 2017 ($MILLION) 153TABLE 61 U.S.: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,2010 – 2017 ($MILLION) 154TABLE 62 U.S.: NASAL DRUG DELIVERY MARKET, BY FORMULATION,2010 – 2017 ($MILLION) 155TABLE 63 U.S.: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,2010 – 2017 ($MILLION) 156TABLE 64 U.S.: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE,2010 – 2017 ($MILLION) 157TABLE 65 U.S.: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION) 158TABLE 66 CANADA: DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION, 2010 – 2017 ($MILLION) 161TABLE 67 CANADA: ORAL DRUG DELIVERY MARKET, BY TECHNOLOGY,2010 – 2017 ($MILLION) 162TABLE 68 CANADA: PULMONARY DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION) 163TABLE 69 CANADA: TRANSDERMAL DRUG DELIVERY MARKET, BY MODE OF DELIVERY, 2010 – 2017 ($MILLION) 164TABLE 70 CANADA: INJECTABLE DRUG DELIVERY MARKET, BY TECHNOLOGY, 2010 – 2017 ($MILLION) 165TABLE 71 CANADA: OCULAR DRUG DELIVERY MARKET, BY FORMULATION,2010 – 2017 ($MILLION) 166TABLE 72 CANADA: NASAL DRUG DELIVERY MARKET, BY FORMULATION,2010 – 2017 ($MILLION) 167TABLE 73 CANADA: TOPICAL DRUG DELIVERY MARKET, BY FORMULATION,2010 – 2017 ($MILLION) 168TABLE 74 CANADA: IMPLANTABLE DRUG DELIVERY MARKET, BY DEVICE TYPE, 2010 – 2017 ($MILLION) 169TABLE 75 CANADA: TRANSMUCOSAL DRUG DELIVERY MARKET, BY MUCOSA TYPE, 2010 – 2017 ($MILLION) 170TABLE 76 MERGERS & ACQUISITIONS, 2011 –2013 173TABLE 77 AGREEMENTS, COLLABORATIONS, JOINT VENTURES & PARTNERSHIPS, 2011 –2013 176TABLE 78 NEW PRODUCT LAUNCH, 2010 – 2012 178TABLE 79 OTHER DEVELOPMENTS, 2010 – 2013 179TABLE 80 3M COMPANY: TOTAL REVENUE, BY SEGMENT, 2009 – 2011 ($MILLION) 189TABLE 81 3M COMPANY: TOTAL REVENUE, BY GEOGRAPHY,2009 – 2011 ($MILLION) 190TABLE 82 BAXTER INTERNATIONAL: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($MILLION) 201TABLE 83 BAXTER INTERNATIONAL: MEDICAL PRODUCTS TOTAL REVENUE,2010 – 2012($MILLION) 201TABLE 84 BAXTER INTERNATIONAL: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 202TABLE 85 BECTON, DICKINSON: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($MILLION) 206TABLE 86 BECTON, DICKINSON: MEDICAL DIVISION TOTAL REVENUE,BY SEGMENT, 2010 – 2012 ($MILLION) 207TABLE 87 BECTON, DICKINSON: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012($MILLION) 207TABLE 88 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE, BY SEGMENT,2009 – 2011 ($MILLION) 213TABLE 89 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,BY SEGMENT, 2010 – 2012 ($MILLION) 221TABLE 90 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE,BY GEOGRAPHY, 2010 – 2012 ($MILLION) 222TABLE 91 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($MILLION) 227TABLE 92 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($MILLION) 233TABLE 93 JOHNSON & JOHNSON, INC.: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 233TABLE 94 THE DOW CHEMICAL COMPANY: TOTAL REVENUE, BY SEGMENT,2010 – 2012 ($MILLION) 252TABLE 95 VALEANT PHARMACEUTICALS: TOTAL REVENUE, BY GEOGRAPHY,2010 – 2012 ($MILLION) 258LIST OF FIGURESFIGURE 1 NORTH AMERICA DRUG DELIVERY MARKET, BY ROUTE OF ADMINISTRATION (2012) 30FIGURE 2 DRUG DELIVERY MARKET SEGMENTATION 34FIGURE 3 MARKET DYNAMICS 37FIGURE 4 PORTER'S FIVE FORCES ANALYSIS FOR DRUG DELIVERY MARKET 49FIGURE 5 VALUE CHAIN ANALYSIS 52FIGURE 6 U.S. PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS,BY KEY PLAYER, 2012 54FIGURE 7 CANADA PULMONARY DRUG DELIVERY: MARKET SHARE ANALYSIS,BY KEY PLAYER, 2012 55FIGURE 8 U.S. TRANSDERMAL DRUG DELIVERY: MARKET SHARE ANALYSIS,BY KEY PLAYER, 2012 56FIGURE 9 CANADA TRANSDERMAL DRUG DELIVERY: MARKET SHARE ANALYSIS, BY KEY PLAYER, 2012 57FIGURE 10 U.S. INJECTABLE DRUG DELIVERY DEVICES MARKET, BY KEY PLAYERS, 2012 58FIGURE 11 CANADA INJECTABLE DRUG DELIVERY DEVICES MARKET,BY KEY PLAYERS, 2012 60FIGURE 12 U.S. IMPLANTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS,BY KEY PLAYER, 2012 61FIGURE 13 CANADA IMPLANTABLE DRUG DELIVERY: MARKET SHARE ANALYSIS,BY KEY PLAYER, 2012 62FIGURE 14 OPPORTUNITY MATRIX: NORTH AMERICA DRUG DELIVERY MARKET (2012) 68FIGURE 15 ORAL DRUG DELIVERY MARKET SHARE (2012) 71FIGURE 16 KEY GROWTH STRATEGIES, 2010 – 2013 171FIGURE 17 3M COMPANY: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($MILLION) 188FIGURE 18 APTALIS PHARMA, INC.: TOTAL REVENUE AND R&D EXPENSES,2009 – 2011 ($MILLION) 195FIGURE 19 BAXTER INTERNATIONAL: TOTAL REVENUE AND R&D EXPENSES,2010 – 2012 ($MILLION) 200FIGURE 20 BECTON, DICKINSON: TOTAL REVENUE AND R&D EXPENDITURE,2010 – 2012 ($MILLION) 206FIGURE 21 CATALENT PHARMA SOLUTIONS: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 213FIGURE 22 TEVA PHARMACEUTICAL INDUSTRIES LIMITED: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 220FIGURE 23 ENDO HEALTH SOLUTIONS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 226FIGURE 24 JOHNSON & JOHNSON, INC.: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 232FIGURE 25 NEKTAR THERAPEUTICS, INC.: TOTAL REVENUE AND R&D EXPENSES, 2009 – 2011 ($MILLION) 239FIGURE 26 PSIVIDA CORPORATION: TOTAL REVENUE, 2009 – 2011 ($MILLION) 247FIGURE 27 THE DOW CHEMICAL COMPANY: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 252FIGURE 28 VALEANT PHARMACEUTICALS: TOTAL REVENUE AND R&D EXPENSES, 2010 – 2012 ($MILLION) 258

To order this report:Drug_Delivery_Technology Industry: North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) – Forecasts To 2017

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Good Shepherd Rehabilitation Network Will Be FIRST In North America To Have Ekso with Variable Assist for Stroke Patients
2. ACTEON North America Launches New Website
3. Frost & Sullivan: Expiration of Patents for Leading Drugs to Bolster the Oral Solid Drug Dosage Excipients Market in North America
4. Millennium HealthCare Signs Exclusive Distribution Agreement with eWellness Corporation for Northeast and Mid-Atlantic Regions
5. Pharmapack North America - Event to Cover Drug Security, Track and Trace, Pharmaceutical Packaging Design and Patient Compliance
6. Edison Expands North American Healthcare Sector Coverage With Initiation of Coverage on Bellus Health
7. China & North East Asia Medical Device Market Reports
8. Northstar acquires a new and exciting patent license in a multi-billion dollar industry
9. Northern Europe Medical Device Market Reports
10. North Shore-LIJ Extends Use of 3rd Party Remote Video Auditing into ORs
11. North Carolina Business Owners At Risk Because Of Defective Medicare Bidding Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 According to a new ... Pen Needles, Safety Pen Needles), Needle Length (4mm, 5mm, ... Mode of Purchase (Retail, Non-Retail) - Trends & Global ... the market for the forecast period of 2016 to ... Billion by 2021 from USD 1.65 Billion in 2016, ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media Slicing Effect ... videos a whole new perspective by using the title layers in ProSlice Levels ... , ProSlice Levels contains over 30 Different presets to choose from. FCPX ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):